-
1.发明授权Method and compositions for the synthesis of dioxolane nucleosides with .beta.-configuration 有权用β-配置合成二氧戊环核苷的方法和组合物
公开(公告)号：US6069250A
公开(公告)日：2000-05-30
申请号：US251431
申请日：1999-02-17
申请人： Tarek Mansour , Alex Cimpoia , Krzysztof Bednarski
发明人： Tarek Mansour , Alex Cimpoia , Krzysztof Bednarski
IPC分类号： C07D473/00 , C07D317/10 , C07D405/04 , C07D473/04 , C07D473/16 , C07D473/18 , C07D473/30 , C07D473/32 , C07D473/34 , C07D473/40 , C07D487/04 , C07H20060101 , C07D239/26
CPC分类号： C07D405/04 , Y02P20/55
摘要： The present invention relates to methods and compositions for preparing biologically important nucleoside analogues containing 1,3-dioxolane sugar rings. In particular, this invention relates to the stereoselective synthesis of the beta (cis) isomer by glycosylating the base with an intermediate of formula (II) below a temperature of about -10.degree. C. ##STR1## wherein R.sub.1 and L are as defined herein.
摘要翻译： 本发明涉及用于制备含有1,3-二氧戊环糖环的生物重要核苷类似物的方法和组合物。 特别地，本发明涉及通过在约-10℃的温度下将式（II）的中间体对碱进行糖基化的β-（顺式）异构体的立体选择性合成，其中R 1和L如本文所定义。
-
2.发明授权Method and compositions for the synthesis of dioxolane nucleosides with .beta. configuration 失效用β配置合成二氧戊环核苷的方法和组合物
公开(公告)号：US5922867A
公开(公告)日：1999-07-13
申请号：US849722
申请日：1997-06-26
申请人： Tarek Mansour , Alex Cimpoia , Krzysztof Bednarski
发明人： Tarek Mansour , Alex Cimpoia , Krzysztof Bednarski
IPC分类号： C07D473/00 , C07D317/10 , C07D405/04 , C07D473/04 , C07D473/16 , C07D473/18 , C07D473/30 , C07D473/32 , C07D473/34 , C07D473/40 , C07D487/04 , C07H20060101
CPC分类号： C07D405/04 , Y02P20/55
摘要： The present invention relates to methods and compositions for preparing biologically important nucleoside analogues containing 1,3-dioxolane sugar rings. In particular, this invention relates to the stereoselective synthesis of the beta (cis) isomer by glycosylating the base with an intermediate of formula (II) below a temperature of about -10.degree. C. ##STR1## wherein R.sub.1 and L are defined herein.
摘要翻译： PCT No.PCT / CA96 / 00845 Sec。 371日期：1997年6月26日 102（e）日期1997年6月26日PCT提交1996年12月13日PCT公布。 WO97 / 21706 PCT公开号 日期：1996年6月19日本发明涉及制备含有1,3-二氧戊环糖环的生物重要核苷类似物的方法和组合物。 特别地，本发明涉及通过在约-10℃的温度下将式（II）的中间体对碱进行糖基化而将β（顺式）异构体的立体选择性合成，其中R 1和L在本文中定义。
-
3.发明授权Pyrimidine-based non-nucleotide composition and method for inhibiting platelet aggregation 失效基于嘧啶的非核苷酸组合物和抑制血小板聚集的方法公开(公告)号：US07932376B2
公开(公告)日：2011-04-26
申请号：US11413600
申请日：2006-04-28
IPC分类号： C07H19/06 , C07H19/067 , C07D239/47 , A61K31/7068 , A61K31/506 , A61P7/02
CPC分类号： C07D493/04 , C07D405/04 , C07H19/12
摘要： This invention is directed to a method of preventing or treating diseases or conditions associated with platelet aggregation. The method is also directed to a method of treating thrombosis or related disorders. The method comprises administering to a subject a pharmaceutical composition comprising an effective amount of a non-nucleotide pyrimidine-based compound, preferably a P2Y12 receptor antagonist compound, wherein said amount is effective to inhibit platelet aggregation. The compounds useful for this invention include compounds of general Formulae I and Ia-Ic, or tautomers, salts, hydrates, and solvates thereof. The present invention also provides novel compounds of Formulae I and Ia-Ic.
摘要翻译： 本发明涉及一种预防或治疗与血小板聚集有关的疾病或病症的方法。 该方法还涉及治疗血栓形成或相关病症的方法。 该方法包括向受试者施用包含有效量的非核苷酸嘧啶类化合物，优选P2Y12受体拮抗剂化合物的药物组合物，其中所述量有效抑制血小板聚集。 可用于本发明的化合物包括通式I和Ia-Ic的化合物，或其互变异构体，盐，水合物和溶剂合物。 本发明还提供式I和Ia-1c的新型化合物。
-
公开(公告)号：US06498196B1
公开(公告)日：2002-12-24
申请号：US09460722
申请日：1999-12-14
申请人： Edward Roberts , Tiechao Li , Dilip Dixit , Krzysztof Bednarski , Dick Storer , Wuyi Wang
发明人： Edward Roberts , Tiechao Li , Dilip Dixit , Krzysztof Bednarski , Dick Storer , Wuyi Wang
IPC分类号： A61K3110
CPC分类号： C07D249/14 , C07C323/30 , C07C323/37 , C07C323/52 , C07C323/60 , C07C323/65 , C07C2602/10 , C07F9/4006
摘要： The present invention relates to novel thio-aminotetralin compounds of the formula (I) wherein Z, X, R1, R2, R3, R4, R5, and R6 are defined herein. The compounds are useful in pain management.
摘要翻译： 本发明涉及式（I）的新型硫代 - 氨基四氢化萘化合物，其中Z，X，R 1，R 2，R 3，R 4，R 5和R 6在本文中定义。 这些化合物可用于疼痛管理。
-
5.发明申请Pyrimidine-based non-nucleotide composition and method for inhibiting platelet aggregation 失效基于嘧啶的非核苷酸组合物和抑制血小板聚集的方法公开(公告)号：US20060258614A1
公开(公告)日：2006-11-16
申请号：US11413600
申请日：2006-04-28
申请人： James Douglass , Paul Watson , Sammy Shaver , Krzysztof Bednarski
发明人： James Douglass , Paul Watson , Sammy Shaver , Krzysztof Bednarski
IPC分类号： A61K31/7072 , A61K31/513 , C07H19/12 , C07D405/02
CPC分类号： C07D493/04 , C07D405/04 , C07H19/12
摘要： This invention is directed to a method of preventing or treating diseases or conditions associated with platelet aggregation. The method is also directed to a method of treating thrombosis or related disorders. The method comprises administering to a subject a pharmaceutical composition comprising an effective amount of a non-nucleotide pyrimidine-based compound, preferably a P2Y12 receptor antagonist compound, wherein said amount is effective to inhibit platelet aggregation. The compounds useful for this invention include compounds of general Formulae I and Ia-Ic, or tautomers, salts, hydrates, and solvates thereof. The present invention also provides novel compounds of Formulae I and Ia-Ic.
摘要翻译： 本发明涉及一种预防或治疗与血小板聚集有关的疾病或病症的方法。 该方法还涉及治疗血栓形成或相关病症的方法。 该方法包括向受试者施用包含有效量的非核苷酸嘧啶类化合物，优选P2Y 12受体拮抗剂化合物的药物组合物，其中所述量有效抑制血小板聚集。 可用于本发明的化合物包括通式I和Ia-Ic的化合物，或其互变异构体，盐，水合物和溶剂合物。 本发明还提供式I和Ia-1c的新型化合物。
-
公开(公告)号：US07132408B2
公开(公告)日：2006-11-07
申请号：US10814007
申请日：2004-03-30
申请人： José L. Boyer , James G. Douglass, III , Sammy R. Shaver , Krzysztof Bednarski , Benjamin R. Yerxa , Gillian M. Olins
发明人： José L. Boyer , James G. Douglass, III , Sammy R. Shaver , Krzysztof Bednarski , Benjamin R. Yerxa , Gillian M. Olins
CPC分类号： C07H19/20 , A61K31/675 , A61K31/7072 , A61K31/7076 , A61K31/7084 , C07H19/04 , C07H19/10 , C07H19/207 , C07H21/00
摘要： This invention is directed to a method of preventing or treating diseases or conditions associated with platelet aggregation. The method is also directed to a method of treating thrombosis. The method comprises administering to a subject a pharmaceutical composition comprising a therapeutic effective amount of P2Y12 receptor antagonist compound, wherein said amount is effective to bind the P2Y12 receptors on platelets and inhibit ADP-induced platelet aggregation. The P2Y12 receptor antagonist compounds useful for this invention include mononucleoside 5′-monophosphates, mononucleoside polyphosphates, and dinucleoside polyphosphates of general Formula I, or salts thereof. The present invention also provides novel compounds of mononucleoside 5′-monophosphates, mononucleoside polyphosphates, and dinucleoside polyphosphates. The present invention further provides pharmaceutical formulations comprising mononucleoside 5′-monophosphates, mononucleoside polyphosphates, or dinucleoside polyphosphates.
摘要翻译： 本发明涉及一种预防或治疗与血小板聚集有关的疾病或病症的方法。 该方法还涉及治疗血栓形成的方法。 该方法包括向受试者施用包含治疗有效量的P2Y 12受体拮抗剂化合物的药物组合物，其中所述量有效结合血小板上的P2Y 12 / 抑制ADP诱导的血小板聚集。 可用于本发明的P2Y 12受体拮抗剂化合物包括单核苷5'-单磷酸酯，单核苷多聚磷酸酯和通式I的二核苷多磷酸盐或其盐。 本发明还提供了单核苷5'-单磷酸酯，单核苷多磷酸盐和二核苷多磷酸的新型化合物。 本发明还提供了包含单核苷5'-单磷酸酯，单核苷多磷酸盐或二核苷多磷酸盐的药物制剂。
-
公开(公告)号：US06844368B1
公开(公告)日：2005-01-18
申请号：US09460723
申请日：1999-12-14
申请人： Edward Roberts , Tiechao Li , Dilip Dixit , Krzysztof Bednarski , Jean-Francois Lavallée , Dick Storer , Wuyi Wang
发明人： Edward Roberts , Tiechao Li , Dilip Dixit , Krzysztof Bednarski , Jean-Francois Lavallée , Dick Storer , Wuyi Wang
IPC分类号： A61K31/135
CPC分类号： C07C217/52 , C07C2602/10 , C07C2603/94
摘要： The present invention relates to novel oxo-aminotetralin compounds of the formula (I) wherein X, R1, R2, R3, R4, R5, and R6 are defined herein. The compounds of formula (I) are useful in pain management.
摘要翻译： 本发明涉及式（I）的新型氧代 - 氨基四氢化萘化合物，其中X，R 1，R 2，R 3，R 4，R 5和R 6在本文中定义。式（I）化合物可用于疼痛管理。
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.023 秒)
